SG11202107578QA - Structured molecular vectors for anti-inflammatory compounds and uses thereof - Google Patents

Structured molecular vectors for anti-inflammatory compounds and uses thereof

Info

Publication number
SG11202107578QA
SG11202107578QA SG11202107578QA SG11202107578QA SG11202107578QA SG 11202107578Q A SG11202107578Q A SG 11202107578QA SG 11202107578Q A SG11202107578Q A SG 11202107578QA SG 11202107578Q A SG11202107578Q A SG 11202107578QA SG 11202107578Q A SG11202107578Q A SG 11202107578QA
Authority
SG
Singapore
Prior art keywords
inflammatory compounds
structured molecular
molecular vectors
vectors
structured
Prior art date
Application number
SG11202107578QA
Inventor
Jacques Bodennec
Amor Belmeguenaï
Selena Bodennec
Laurent Bezin
Béatrice Georges
Victor Blot
Original Assignee
Univ Claude Bernard Lyon
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Jean Monnet Saint Etienne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Claude Bernard Lyon, Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Jean Monnet Saint Etienne filed Critical Univ Claude Bernard Lyon
Publication of SG11202107578QA publication Critical patent/SG11202107578QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4009Esters containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03Organic compounds
    • A23L29/035Organic compounds containing oxygen as heteroatom
    • A23L29/04Fatty acids or derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ophthalmology & Optometry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202107578QA 2019-02-21 2020-02-21 Structured molecular vectors for anti-inflammatory compounds and uses thereof SG11202107578QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305212 2019-02-21
EP19306376 2019-10-23
PCT/EP2020/054662 WO2020169822A1 (en) 2019-02-21 2020-02-21 Structured molecular vectors for anti-inflammatory compounds and uses thereof

Publications (1)

Publication Number Publication Date
SG11202107578QA true SG11202107578QA (en) 2021-08-30

Family

ID=69593711

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107578QA SG11202107578QA (en) 2019-02-21 2020-02-21 Structured molecular vectors for anti-inflammatory compounds and uses thereof

Country Status (12)

Country Link
US (1) US20220162239A1 (en)
EP (1) EP3927348A1 (en)
JP (1) JP2022521414A (en)
KR (2) KR20220082117A (en)
CN (1) CN113677349B (en)
AU (1) AU2020225354A1 (en)
BR (1) BR112021015307A2 (en)
CA (1) CA3126203A1 (en)
IL (1) IL284712A (en)
MX (1) MX2021009328A (en)
SG (1) SG11202107578QA (en)
WO (1) WO2020169822A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
SE9900941D0 (en) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1469083A1 (en) 2003-04-17 2004-10-20 Centre National De La Recherche Scientifique (Cnrs) Method of calibration of reverse transcription using a synthetic messenger RNA (smRNA) as an internal control
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7579468B2 (en) * 2005-09-15 2009-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2011113507A2 (en) * 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
AU2015242791B2 (en) * 2014-04-04 2017-08-17 Osaka University Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
CA3040258A1 (en) * 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
FR3063645B1 (en) 2017-03-08 2021-06-11 Lipther ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE DEPENDENT DISEASES
US20180303821A1 (en) * 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules

Also Published As

Publication number Publication date
US20220162239A1 (en) 2022-05-26
JP2022521414A (en) 2022-04-07
AU2020225354A8 (en) 2021-09-02
CN113677349A (en) 2021-11-19
IL284712A (en) 2021-08-31
CA3126203A1 (en) 2020-08-27
EP3927348A1 (en) 2021-12-29
CN113677349B (en) 2024-03-19
KR102411189B1 (en) 2022-06-23
WO2020169822A1 (en) 2020-08-27
AU2020225354A1 (en) 2021-08-12
KR20220082117A (en) 2022-06-16
MX2021009328A (en) 2021-11-12
BR112021015307A2 (en) 2021-11-09
KR20210042385A (en) 2021-04-19

Similar Documents

Publication Publication Date Title
EP3583507A4 (en) Blockchain-based admission processes for protected entities
IL285178A (en) Compounds and uses thereof
GB201905265D0 (en) Inflammasome inhibition
IL285177A (en) Compounds and uses thereof
EP3762391A4 (en) Spirocentric compounds and polymers thereof
IL278142A (en) Antiproliferation compounds and uses thereof
IL286497A (en) Compounds and uses thereof
EP3962431A4 (en) Rinse-free shampoo composition
IL288412A (en) Peptides
IL291499A (en) Aza-quinoline compounds and uses thereof
IL284764A (en) Compounds and uses thereof
AU2018301804A1 (en) Molecular guide system peptides and uses thereof
IL291260A (en) Anthranilamide composition
IL285118A (en) Compounds and uses thereof
EP3448309A4 (en) Ifetroban treatment for systemic sclerosis
IL284712A (en) Structured molecular vectors for anti-inflammatory compounds and uses thereof
EP3416975A4 (en) Novel alpha conotoxin peptides
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3980440A4 (en) Anti-inflammatory agents
EP3898652A4 (en) Mitochondria-targeting peptides
EP3841108A4 (en) Pharmaceutical compositions comprising integration-promoting peptides
ZA202201239B (en) Aminothiolester compounds and uses thereof
IL282062A (en) Vinaigrette
EP3818070A4 (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
AU2019901968A0 (en) Anti-inflammatory agents